AstraZeneca CEO hails NHS drug price deal but keeps pause on £200m UK investment

AstraZeneca Chief Executive Pascal Soriot announced during a corporate update in London on February 10, 2026, that the pharmaceutical giant will maintain its freeze on a planned £200 million investment in its Cambridge research facility despite a new pricing agreement between the UK government and the industry. While Soriot praised the recent Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) as a positive step toward stabilizing the market, he clarified that the deal alone is insufficient to justify resuming the expansion of the company's UK footprint. The decision highlights ongoing tensions between the life sciences sector and the National Health Service (NHS) over budgetary constraints and clinical trial competitiveness. The proposed investment, which was originally intended to turn the Cambridge site into a premier global hub for oncology and rare disease research, was paused last year amid concerns over the high levies the UK government places on drug revenues. Under the current system, pharmaceutical companies must pay a percentage of their sales back to the government if the NHS's total spending on branded medicines exceeds a specific growth cap. Soriot argued that while the new agreement offers more predictability than previous iterations, the overall fiscal environment in Britain remains challenging compared to rival markets in the United States and Europe. Beyond tax and pricing concerns, AstraZeneca has expressed frustration with the bureaucratic hurdles of the UK’s clinical trial infrastructure. The company noted that the speed at which new treatments are approved and adopted by the NHS has lagged behind international peers, making it difficult to justify massive capital expenditures in the domestic market. For the UK government, the continued pause on the £200 million project represents a significant blow to its public ambitions of transforming the country into a post-Brexit "science superpower." Industry analysts suggest that the standoff is a strategic signal to the Treasury, as the pharmaceutical sector seeks further incentives, such as R&D tax credits and improved access to patient data for research. AstraZeneca remains the UK’s largest drugmaker by market value, and its investment decisions are often seen as a bellwether for the health of the nation's broader life sciences ecosystem. For now, the company has indicated it will continue to monitor the practical impact of the new pricing deal before committing to further long-term infrastructure projects in Britain.